ReleaseWire

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided an overview of the Company's 2014 achievements and a business update for 2015. The stated achievements and highlights below demonstrate the significant progress the Company has made on key initiatives to support the advancement of the ongoing Phase 1/2 program and upcoming Phase 3 clinical development program for Actimab-A and Iomab-B, respectively.

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has a new presentation slot at the 27th Annual ROTH Capital Partners Conference which is being held on March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel in Dana Point, California.

The winter frost isn't the only thing affecting our nation's crops, according to the Purdue University Weed Science team. The team is working hard to educate food growers on a major culprit: herbicide-resistant weeds to be exact. Food growers across the country are finding it increasingly difficult to kill "super weeds" as they become resistant to the most popular herbicides. After years of constant exposure to these herbicides, certain invasive plants have also developed a resistance, leading farmers to use more of the chemical. In some cases, the weeds have grown completely tolerant to these chemicals, allowing them to grow as high as eight feet tall.

As part of American Heart Month, Feb. 6 has been dubbed National Wear Red Day. It was created to acknowledge the one in three women every year whose deaths are related to stroke and heart disease. Prescription medicines are often used in the front lines against this epidemic. Medicationdiscountcard.com offers discount cards for many of these prescriptions.

DelMar Pharmaceuticals, Inc. (DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application number 13/817,096 entitled, "Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol."

SIGNiX, the leading provider of Independent E-Signatures™, announced today that it has launched PharmaDoX, the pharmaceutical industry's first digital signature service created to relieve paperwork burdens of clinical trials. PharmaDoX makes it easy for sponsors, clinical research organizations (CROs), investigators and patients to sign clinical trial documents online while adhering to FDA regulations. This ready-made solution incorporates the requirements of the FDA's 21 CFR Part 11 rule.

Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced positive results from the six month animal study of Lacto-Freedom™, the company's lactase producing probiotic. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.

FyMed is advancing targeted candidates for both early and advanced colorectal cancer. FY405B is an investigational cancer targeted cytotoxic therapy, a new class of treatments that use the body's own selective pathways to help fight cancer. FyMed has developed substantial preclinical evidence that its drug candidate, FY405B, could effectively kill colon cancer cells through in-vitro studies as well as in animal models of colon cancer.

Despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy according to a recent paper in Current Opinion in Oncology.

Global Markets Direct's, 'Japanese Encephalitis - Pipeline Review, H2 2014', provides an overview of the Japanese Encephalitis's therapeutic pipeline.

OTC Medications in Sweden by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Sweden is given in SEK with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Sweden. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it acquired the worldwide rights to the Fluticare(TM) brand (Fluticasone propionate nasal spray) from Novalere FP., Inc. ("Novalere") through a merger.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors. Prior to founding TurckBio, Dr. Turck led Bayer Healthcare's Global Specialty Medicine unit, where most relevant to Actinium, he played a leadership role in the commercialization of the alpha-radiopharmaceutical Xofigo® whose successful launch he prepared in close collaboration with Algeta ASA.

OTC Medications in Italy by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Italy is given in EUR with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Italy. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Global Markets Direct's, 'Nuevolution A/S - Product Pipeline Review - 2014', provides an overview of the Nuevolution A/S's pharmaceutical research and development focus.

Global Markets Direct's, 'HAL Allergy BV - Product Pipeline Review - 2014', provides an overview of the HAL Allergy BV's pharmaceutical research and development focus.

Global Markets Direct's, 'Panmira Pharmaceuticals, LLC. - Product Pipeline Review - 2014', provides an overview of the Panmira Pharmaceuticals, LLC.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Peripheral Neuropathic Pain's therapeutic pipeline.

GlobalData's clinical trial report, "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014" provides data on the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Clostridium Difficile Infections (Clostridium Difficile Associated Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Clostridium Difficile Infections (Clostridium Difficile Associated Disease). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NovaDigm Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Cleveland BioLabs, Inc. - Product Pipeline Review - 2014', provides an overview of the Cleveland BioLabs, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Parion Sciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Parion Sciences, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'NeoStem, Inc. - Product Pipeline Review - 2014', provides an overview of the NeoStem, Inc.'s pharmaceutical research and development focus.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and vitality, announced today that it entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Androferti®, a patented and clinically proven product to support male reproductive health and sperm quality, in the U.S. and Canada.